CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018

ZUG, Switzerland and CAMBRIDGE, Mass., April 13, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics CRSP, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the Company is scheduled to present new data on its allogeneic CRISPR-based CAR-T programs at the American Association for Cancer Research (AACR) Annual Meeting on Monday, April 16, 2018 in Chicago, IL.

Presentation: Allogeneic chimeric antigen receptor T cells targeting B cell maturation antigen

Session: Adoptive Cell Therapy 1

Time and Date: 8:00 AM – 12:00 PM CDT, Monday, April 16, 2018

Location: McCormick Place South (Level 3), Exhibit Hall A, Section 24, Poster 1540

Presentation: Allogeneic CRISPR engineered anti CD70 CAR T cells demonstrate potent preclinical activity against both solid and hematological cancer cells

Session: Adoptive Cell Therapy 2

Time and Date: 1:00 PM - 5:00 PM CDT, Monday, April 16, 2018

Location: McCormick Place South (Level 3), Exhibit Hall A, Section 24, Poster 2551  

Following presentation at the meeting, the posters will be available on CRISPR Therapeutics' website at http://www.crisprtx.com.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. The Company has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.

CONTACTS

CRISPR Therapeutics

Investors:

Chris Erdman

617-307-7227

chris.erdman@crisprtx.com

or

Chris Brinzey

Westwicke Partners

339-970-2843

chris.brinzey@westwicke.com

Media:

Jennifer Paganelli

WCG for CRISPR

347-658-8290

jpaganelli@wcgworld.com